申请人:BUTTERWORTH Sam
公开号:US20130053409A1
公开(公告)日:2013-02-28
The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.
本发明涉及某些2-(2,4,5-取代苯胺基)嘧啶化合物及其药学上可接受的盐,这些化合物可能对通过某些突变表皮生长因子受体介导的疾病或医疗状况(例如L858R激活突变体、Exon19缺失激活突变体和T790M耐药突变体)的治疗或预防有用。这些化合物及其盐可能对多种不同的癌症的治疗或预防有用。本发明还涉及包含这些化合物及其盐的药物组合物,特别是这些化合物及其盐的有用多形式,以及用于制造这些化合物的中间体和使用这些化合物及其盐治疗通过不同形式的EGFR介导的疾病的方法。